Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, has announced new employee inducement equity awards. The company granted stock options for 30,000 shares at $1.12 per share to one new non-executive employee and restricted stock units (RSUs) for 37,900 shares to two new non-executive employees.
The awards, approved by the Compensation Committee and granted under the company's Amended and Restated Inducement Equity Plan, include a 4-year vesting schedule. Stock options vest 25% after one year with remaining monthly installments over 36 months, while RSUs vest 25% annually over four years.
Fate Therapeutics (NASDAQ: FATE), un'azienda biofarmaceutica in fase clinica specializzata in immunoterapie cellulari derivate da iPSC, ha annunciato nuovi premi azionari per l'assunzione di dipendenti. La societ脿 ha concesso opzioni su azioni per 30.000 azioni a 1,12 $ per azione a un nuovo dipendente non esecutivo e unit脿 azionarie vincolate (RSU) per 37.900 azioni a due nuovi dipendenti non esecutivi.
I premi, approvati dal Comitato per la Retribuzione e concessi nell'ambito del Piano Azionario di Induzione Emendato e Ristabilito dell'azienda, prevedono un programma di maturazione di 4 anni. Le opzioni su azioni maturano il 25% dopo un anno, con rate mensili per i restanti 36 mesi, mentre le RSU maturano il 25% ogni anno per quattro anni.
Fate Therapeutics (NASDAQ: FATE), una compa帽铆a biofarmac茅utica en etapa cl铆nica centrada en inmunoterapias celulares derivadas de iPSC, ha anunciado nuevas concesiones de acciones para empleados. La empresa otorg贸 opciones sobre 30,000 acciones a $1.12 por acci贸n a un nuevo empleado no ejecutivo y unidades de acciones restringidas (RSU) por 37,900 acciones a dos nuevos empleados no ejecutivos.
Las concesiones, aprobadas por el Comit茅 de Compensaci贸n y otorgadas bajo el Plan de Acciones de Inducci贸n Enmendado y Reestablecido de la compa帽铆a, incluyen un programa de adquisici贸n de derechos de 4 a帽os. Las opciones sobre acciones se adquieren en un 25% despu茅s de un a帽o, con cuotas mensuales durante los siguientes 36 meses, mientras que las RSU se adquieren en un 25% anual durante cuatro a帽os.
Fate Therapeutics (NASDAQ: FATE)電� iPSC 鞙犽灅 靹疙彫 氅挫棴旃橂鞝滌棎 欷戩爯鞚� 霊� 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎� 須岇偓搿�, 鞁犼窚 歆侅洂 鞙犾澑 欤检嫕 氤挫儊鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 頃� 氇呾潣 牍勳瀯鞗� 鞁犾瀰 歆侅洂鞐愱矊 欤茧嫻 1.12雼煬鞐� 30,000欤检棎 雽�頃� 鞀ろ啞 鞓奠厴鞚�, 霊� 氇呾潣 牍勳瀯鞗� 鞁犾瀰 歆侅洂鞐愱矊 37,900欤检棎 雽�頃� 鞝滍暅 欤检嫕 雼渼(RSU)毳� 攵�鞐枅鞀惦媹雼�.
鞚� 氤挫儊鞚� 氤挫儊鞙勳洂須岇潣 鞀轨澑鞚� 氚涭晞 須岇偓鞚� 靾橃爼 氚� 鞛爼牍勲悳 鞙犾澑 欤检嫕 瓿勴殟鞐� 霐半澕 攵�鞐悩鞐堨溂氅�, 4雲� 氩犾姢韺� 鞚检爼鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. 鞀ろ啞 鞓奠厴鞚� 1雲� 頉� 25%臧� 氩犾姢韺呺悩氅�, 雮橂ǜ歆�電� 36臧滌洈 霃欖晥 毵れ洈 攵勴暊 氩犾姢韺呺悩瓿�, RSU電� 4雲勳棎 瓯胳硱 毵る厔 25%鞌� 氩犾姢韺呺惄雼堧嫟.
Fate Therapeutics (NASDAQ : FATE), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans les immunoth茅rapies cellulaires d茅riv茅es de iPSC, a annonc茅 de nouvelles attributions d'actions incitatives pour les employ茅s. La soci茅t茅 a accord茅 des options d'achat d'actions pour 30 000 actions 脿 1,12 $ par action 脿 un nouvel employ茅 non cadre et des unit茅s d'actions restreintes (RSU) pour 37 900 actions 脿 deux nouveaux employ茅s non cadres.
Ces attributions, approuv茅es par le Comit茅 de r茅mun茅ration et accord茅es dans le cadre du Plan d'attribution d'actions incitatives modifi茅 et r茅vis茅 de la soci茅t茅, comprennent un calendrier d'acquisition de droits de 4 ans. Les options d'achat d'actions acqui猫rent 25 % des droits apr猫s un an, avec des versements mensuels sur les 36 mois suivants, tandis que les RSU acqui猫rent 25 % des droits chaque ann茅e pendant quatre ans.
Fate Therapeutics (NASDAQ: FATE), ein biopharmazeutisches Unternehmen in der klinischen Phase mit Fokus auf iPSC-abgeleitete zellul盲re Immuntherapien, hat neue Aktienanreizpr盲mien f眉r Mitarbeiter angek眉ndigt. Das Unternehmen gew盲hrte Aktienoptionen f眉r 30.000 Aktien zu 1,12 $ pro Aktie an einen neuen nicht gesch盲ftsf眉hrenden Mitarbeiter und Restricted Stock Units (RSUs) f眉r 37.900 Aktien an zwei neue nicht gesch盲ftsf眉hrende Mitarbeiter.
Die Pr盲mien, genehmigt vom Verg眉tungsausschuss und gew盲hrt im Rahmen des ge盲nderten und neu gefassten Inducement Equity Plans des Unternehmens, beinhalten einen 4-j盲hrigen Vesting-Zeitplan. Aktienoptionen werden zu 25 % nach einem Jahr f盲llig, mit monatlichen Raten 眉ber die verbleibenden 36 Monate, w盲hrend RSUs j盲hrlich zu 25 % 眉ber vier Jahre vesten.
- None.
- None.
SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on July 2, 2025 the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 30,000 shares of the Company鈥檚 common stock at an exercise price per share of
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company鈥檚 pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit .
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
[email protected]
FAQ
What equity awards did Fate Therapeutics (FATE) grant to new employees in July 2025?
What is the vesting schedule for Fate Therapeutics' July 2025 employee stock options?
How do the RSUs vest in Fate Therapeutics' July 2025 employee inducement awards?
What was the exercise price for Fate Therapeutics' July 2025 employee stock options?
